Bibliografisk note

Funding Information:
AJS has received Honoraria for speaker events from Teva. Consulting fees from Invex therapeutics; salary and stockholding with Invex therapeutics. Received research funding from the Medical Research Council, National Institute for Health Research, Sir Jules Thorn Trust and the UK Space Agency.

Funding Information:
RHJ has received honoraria for oral presentations from Lectures for Pfizer, Eli-Lilly, ATI, Merck, TEVA, Novartis, Lundbeck and Allergan. She is investigator in clinical trials with ATI, Eli-Lilly, Novartis and Lundbeck and Director of Danish Headache Center, Lifting The Global Burden of Headache and Founder of Master of Headache Disorders at University of Copenhagen. Received research funding from University of Copenhagen, Rigshospitalet, ATI, Lundbeck Foundation, The Medical Society in Copenhagen, NovoNordisk Foundation and Tryg Foundation.

Funding Information:
KBD is supported in part by an Unrestricted Grant from Research to Prevent Blindness, New York, NY, to the Department of Ophthalmology & Visual Sciences, University of Utah.

Funding Information:
RBL reports no conflicts of interest. MJ reports no conflicts of interest. MT reports no conflicts of interest. KB reports no conflicts of interest. MJD reports no conflicts of interest. CT has received received compensation for scientific advice and/or speaking activities for Allergan/Abbvie, Dompé, Eli Lilly, Novartis, Lundbeck, Teva and MDweb. GMT reports consultancy or industry support from Novartis, Lilly and Teva, Allergan/Abbvie, and Lundbeck and independent support from the European Community, Dutch Heart Foundation, IRRF, Dioraphte, and Dutch Brain Council.

Funding Information:
HCD received honoraria for participation in clinical trials, contribution to advisory boards or oral presentations from: Lilly, Novartis, Pfizer, Teva, Weber & Weber and WebMD. The German Research Council (DFG), the German Ministry of Education and Research (BMBF) and the European Union support headache research by HCD. HCD serves on the editorial boards of Cephalalgia, Lancet Neurology and Drugs. HCD is a member of the Clinical Guidelines Committee of the German Society of Neurology and of the Clinical Trials Committee of the IHS.

Funding Information:
SPM has received honoraria for speaker events from Heidelberg engineering; Chugai-Roche Ltd and Teva. Honoraria for advisory boards for Invex Therapeutics and Gensight. Consultancy fees Neurodiem and Invex Therapeutics. Research funding from the UK Space Agency.

Publisher Copyright:
© International Headache Society 2023.